BMS-955176
BMS-955176 is an antiviral drug that was under development by Bristol-Myers Squibb for the treatment of HIV infection. It is a second-generation maturation inhibitor, a class of drugs that interfere with the final stage of the HIV life cycle.
History[edit]
BMS-955176 was developed as a follow-up to bevirimat, the first maturation inhibitor to reach clinical trials. Bevirimat showed promise in early trials, but its effectiveness was limited by naturally occurring variations in the HIV virus. BMS-955176 was designed to overcome these limitations and showed activity against a wider range of HIV variants in preclinical studies.
Mechanism of Action[edit]
As a maturation inhibitor, BMS-955176 interferes with the final step in the HIV life cycle, the conversion of the immature virus particle into a mature, infectious virus. It does this by binding to the Gag protein, a key structural protein of the virus, and preventing it from being cleaved by the viral protease enzyme. This leaves the virus in an immature state and unable to infect new cells.
Clinical Trials[edit]
BMS-955176 has been tested in Phase IIb clinical trials. The results showed that the drug was generally well tolerated and had a similar efficacy to other antiretroviral drugs when used in combination therapy. However, development of the drug was discontinued in 2016 for reasons that were not publicly disclosed.
See Also[edit]
BMS-955176[edit]
-
BMS-955176
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian